

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT					
NATURE OF CONVEYANCE:	ASSIGNMENT					
CONVEYING PARTY DATA						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%; text-align: center;">Name</td> <td style="width: 30%; text-align: center;">Execution Date</td> </tr> <tr> <td>DAIICHI SANKYO COMPANY, LIMITED</td> <td>03/14/2008</td> </tr> </table>		Name	Execution Date	DAIICHI SANKYO COMPANY, LIMITED	03/14/2008	
Name	Execution Date					
DAIICHI SANKYO COMPANY, LIMITED	03/14/2008					
RECEIVING PARTY DATA						
Name:	METABASIS THERAPEUTICS, INC.					
Street Address:	11119 NORTH TORREY PINES ROAD					
City:	LA JOLLA					
State/Country:	CALIFORNIA					
Postal Code:	92037					
PROPERTY NUMBERS Total: 1						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; text-align: center;">Property Type</td> <td style="width: 70%; text-align: center;">Number</td> </tr> <tr> <td>Application Number:</td> <td>09900364</td> </tr> </table>		Property Type	Number	Application Number:	09900364	
Property Type	Number					
Application Number:	09900364					
CORRESPONDENCE DATA						
Fax Number:	(352)372-5800					
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>						
Phone:	3523758100					
Email:	FCE@SLSPATENTS.COM					
Correspondent Name:	FRANK C. EISENSCHENK, PH.D.					
Address Line 1:	P.O. BOX 142950					
Address Line 4:	GAINESVILLE, FLORIDA 32614-2950					
ATTORNEY DOCKET NUMBER:	MET-037CXT					
NAME OF SUBMITTER:	FRANK C. EISENSCHENK, PH.D.					
Total Attachments: 3 source=AsgnSank2Met#page1.tif source=AsgnSank2Met#page2.tif source=AsgnSank2Met#page3.tif						

OP \$40.00 09900364

500488038

PATENT
REEL: 020653 FRAME: 0616

ASSIGNMENT

WHEREAS, DAIICHI SANKYO COMPANY, LIMITED of 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426, Japan, and METABASIS THERAPEUTICS, INC. of 11119 North Torrey Pines Road, La Jolla, CA 92037, USA, a U.S. company, are joint assignees/applicants for the applications/Letters Patent identified on Appendix A, attached hereto.

WHEREAS, METABASIS THERAPEUTICS, INC. is desirous of acquiring the entire right, title, and interest in and to the claimed subject matter of the inventions identified on Appendix A and in and to any Letters Patent which may be granted therefor in the United States and any foreign countries.


NOW, THEREFORE, DAIICHI SANKYO COMPANY, LIMITED, in consideration of at least one dollar (\$1.00) and other good and valuable consideration, receipt of which is hereby acknowledged, has sold, assigned, and transferred, and by these presents do sell, assign, and transfer, unto said METABASIS THERAPEUTICS, INC., its successors and assigns, the full and exclusive right to the claimed subject matter of the inventions identified on Appendix A and the entire right, title, and interest in and to any and all Letters Patent which may be granted therefor in the United States, its territorial possessions and any foreign countries and in and to any and all divisions, reissues, continuations, and extensions thereof.

DAIICHI SANKYO COMPANY, LIMITED hereby authorizes and requests the Patent Office Officials in the United States and any foreign countries to issue any and all of said Letters Patent, when granted, to said METABASIS THERAPEUTICS, INC., as the assignee of the entire right, title, and interest in and to the same, for the sole use and behoof of said METABASIS THERAPEUTICS, INC., its successors and assigns.

FURTHER, DAIICHI SANKYO COMPANY, LIMITED agrees that it will communicate to said METABASIS THERAPEUTICS, INC., or its representatives, any facts known to it respecting said invention; testify in any legal proceedings; sign all lawful papers; execute all divisional, continuation, substitution, renewal, and reissue applications for the subject matter claimed in said application; execute all necessary assignment papers to cause any and all of said Letters Patent to be issued to said METABASIS THERAPEUTICS, INC.; make all rightful oaths; and generally do everything possible to aid the said METABASIS THERAPEUTICS, INC., its successors and assigns, to obtain and enforce proper protection for said invention in the United States and any foreign countries.

Executed this 14th day of March, 2008.

DAIICHI SANKYO COMPANY, LIMITED



Printed Name: Tsutomu Une

Title: Member of the Board and Senior Executive Officer

Date: March 14, 2008

WITNESS:



Printed Name: Kazuo Sato

APPENDIX A

Application/Patent No.	Country	Filing Date	Docket No.
60/215,126	United States	June 29, 2000	MET-037PT
60/216,531	United States	July 6, 2000	MET-037CPT
09/900,364	United States	July 5, 2001	MET-037CXT
11/841,933	United States	Aug. 20, 2007	MET-037CXTD1
2001273271	Australia	July 5, 2001	MET-037CXT AU
2006201410	Australia	July 5, 2001	MET-037CXDIV1T AU
PI0112212-6	Brazil	July 5, 2001	MET-037CXT BR
2,412,142	Canada	July 5, 2001	MET-037CXT CA
01814924.3	China	July 5, 2001	MET-037CXT CN
PV2003-5	Czech Republic	July 5, 2001	MET-037CXT CZ
01952530.2	EPO	July 5, 2001	MET-037CXT EPO
04104730.3	Hong Kong	July 5, 2001	MET-037CXT HK
P0301830	Hungary	July 5, 2001	MET-037CXT HU
W-00200202977	Indonesia	July 5, 2001	MET-037CXT ID
153513	Israel	July 5, 2001	MET-037CXT IL
IN/PCT/2002/01873/MUM	India	July 5, 2001	MET-037CXT IN
2002-508433	Japan	July 5, 2001	MET-037CXT JP
10-2003-7000126	Republic of Korea	July 5, 2001	MET-037CXT KR
PA/a/2002/012713	Mexico	July 5, 2001	MET-037CXT MX
20030034	Norway	July 5, 2001	MET-037CXT NO
523227	New Zealand	July 5, 2001	MET-037CXT NZ
PCT/US01/21557	PCT	July 5, 2001	MET-037CXT PCT
P365779	Poland	July 5, 2001	MET-037CXT PL
2003103436	Russia	July 5, 2001	MET-037CXT RU
93654	Singapore	July 5, 2001	MET-037CXT SG
PP6-2003	Slovakia	July 5, 2001	MET-037CXT SK
1-2003-00101	Viet Nam	July 5, 2001	MET-037CXT VN
2003/0044	South Africa	July 5, 2001	MET-037CXT ZA

PATENT

RECORDED: 03/14/2008

REEL: 020653 FRAME: 0619